Long-term testosterone therapy (TTh) with injectable testosterone undecanoate significantly improved glycemic control and led to diabetes remission in men with hypogonadism and type 2 diabetes mellitus (T2DM) over an 11-year observational study. Among the 178 testosterone-treated patients, 34.3% achieved diabetes remission, 46.6% attained normal glucose regulation, and over 80% reached
